Evidence map›Paper›PMID 42232511›Full record

ArticleJAMIA open2026

Using sentiment analysis to quantify the relative desirability and acceptability of drug-product attributes.

Chiril Calin, Maria Deligianni, Brett R South, Ajit Jadhav, Michael Rocco, Zachary Furqueron, Brett Hauber, Stephen J Watt

Abstract read
In one paragraph

Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiril CalinPfizer Inc., New York, NY 10001, United States.
Maria DeligianniPfizer Centre for Digital Innovation, Thessaloniki 555 35, Greece.
Brett R SouthPfizer Inc., New York, NY 10001, United States.
Ajit JadhavPfizer Inc., New York, NY 10001, United States.
Michael RoccoPfizer Inc., New York, NY 10001, United States.
Zachary FurqueronPfizer Inc., New York, NY 10001, United States.
Brett HauberPfizer Inc., New York, NY 10001, United States.
Stephen J WattPfizer Inc., New York, NY 10001, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Patient adherence to medication may be influenced by preferences regarding drug-product attributes. Product quality complaints (PQC) and medical information (MI) requests are a potential source of evidence on patients' preferences. The objective of this study was to demonstrate an approach for extracting and categorizing PQC and MI data using natural language processing (NLP) and quantify the relative desirability and acceptability of attributes of oral solid dosage formulations using sentiment analysis. Materials and Methods: Data of over 20 000 records of PQC and MI requests from Europe between 2022 and 2023 were extracted and analyzed with the use of pretrained artificial intelligence (AI) and NLP components. First, the data extraction pipelines were built through an iterative frequency analysis process, which involved developing a refined set of key search terms, synonyms, and derivatives relevant to the physical attributes of drug formations. These data pipelines served to create a training set for a transformer-based classification model. Then, sentiment analysis assessed the strength and direction of patient sentiment surrounding each relevant search term. Results: The highest frequency of communication records and inquiries were related to "swallowability," "palatability," and "texture," with an overlap between swallowability and size categories. Palatability-related attributes elicited the strongest negative sentiment from patients. Discussion: This study utilized Conclusion: The findings of this study can have implications on drug development to avoid attributes viewed negatively by patients, thereby improving patients' medication-taking experience, treatment adherence, and satisfaction.

Indexed as

DistilBERTdrug-product attributepatient preferencesentiment analysistransformer model

Identifiers

PMID42232511
PMCPMC13223737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.